Valuation Abbott Laboratories Bulgaria S.E.
Stocks
ABL
US0028241000
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.47 EUR | +15.38% |
|
0.00% | -30.19% |
| 07-06 | Evercore ISI Adjusts Abbott Laboratories Price Target to $112 From $120 | MT |
| 07-02 | Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 166,570 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -23.54% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 178,259 | 175,426 | 171,528 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -19.8% | -1.59% | -2.22% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 23.7x | 20.2x | 17.6x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.37x | 3.23x | 3.01x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | 2.73x | 1.2x | 1.2x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.31x | 3.04x | 2.84x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.55x | 3.2x | 2.93x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 13.3x | 12x | 10.7x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 15.3x | 13.5x | 11.9x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 20.6x | 18.6x | 16.5x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 4.86% | 5.37% | 6.05% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.547 | 2.715 | 2.866 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.66% | 2.84% | 3% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 4.043 | 4.736 | 5.437 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 63% | 57.3% | 52.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,256 | 54,748 | 58,610 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,414 | 14,578 | 15,961 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,665 | 13,038 | 14,362 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 7,018 | 8,389 | 9,226 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 11,689 | 8,857 | 4,959 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 95.63 | 95.63 | 95.63 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,741,813 | - | - |
| Announcement Date | 1/26/22 A | 1/25/23 A | 1/24/24 A | 1/22/25 A | 1/22/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.83x | 3.29x | 11.58x | 3.57% | 106B | |
| 16.41x | 0.19x | 11.74x | 0.79% | 58.09B | |
| 32.33x | 7.85x | 20.51x | 1.24% | 52.7B | |
| 38.76x | 3.06x | 10.51x | 2.48% | 42.86B | |
| 40.92x | 1.47x | 12.92x | 0.19% | 36.15B | |
| 29.57x | 5.27x | 16.8x | -.--% | 27.93B | |
| 42.47x | 7.36x | 26.56x | 0.25% | 25.27B | |
| 23.46x | 3.43x | 12.34x | 1.23% | 20.79B | |
| 20.27x | 2.8x | 10.89x | 1.56% | 20.84B | |
| Average | 29.22x | 3.86x | 14.87x | 1.26% | 43.44B | |
| Weighted average by Cap. | 27.14x | 3.63x | 14.16x | 1.71% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABL Stock
- Valuation Abbott Laboratories
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
